These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 19263796)

  • 21. Is there a role for erythropoietin in cardiovascular disease?
    Vogiatzi G; Briasoulis A; Tousoulis D; Papageorgiou N; Stefanadis C
    Expert Opin Biol Ther; 2010 Feb; 10(2):251-64. PubMed ID: 20028188
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Erythropoietin and treatment of non-anemic conditions--cardiovascular protection.
    Fliser D; Haller H
    Semin Hematol; 2007 Jul; 44(3):212-7. PubMed ID: 17631185
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Erythropoietin and the heart: physiological effects and the therapeutic perspective.
    Sanchis-Gomar F; Garcia-Gimenez JL; Pareja-Galeano H; Romagnoli M; Perez-Quilis C; Lippi G
    Int J Cardiol; 2014 Feb; 171(2):116-25. PubMed ID: 24377712
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Erythropoietin in cardiac disease: effective or harmful?
    Mastromarino V; Musumeci MB; Conti E; Tocci G; Volpe M
    J Cardiovasc Med (Hagerstown); 2013 Dec; 14(12):870-8. PubMed ID: 23811836
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Research advances in expression and functions of erythropoietin and erythropoietin receptor in cancers].
    Li M; Lu Y; Chen XQ
    Ai Zheng; 2008 Jun; 27(6):667-72. PubMed ID: 18570746
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Recent advances and clinical application of erythropoietin and erythropoiesis-stimulating agents.
    Tanaka T; Nangaku M
    Exp Cell Res; 2012 May; 318(9):1068-73. PubMed ID: 22414872
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Novel renoprotective actions of erythropoietin: new uses for an old hormone.
    Johnson DW; Forman C; Vesey DA
    Nephrology (Carlton); 2006 Aug; 11(4):306-12. PubMed ID: 16889570
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The pleiotropic effects of erythropoietin in the central nervous system.
    Buemi M; Cavallaro E; Floccari F; Sturiale A; Aloisi C; Trimarchi M; Corica F; Frisina N
    J Neuropathol Exp Neurol; 2003 Mar; 62(3):228-36. PubMed ID: 12638727
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Erythropoietin as a protective agent in myocardial ischemia].
    Schwartzenberg S; Keren G; George J
    Harefuah; 2006 May; 145(5):380-3, 396. PubMed ID: 16805223
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Erythropoietin reduces necrosis in critically ischemic myocutaneous tissue by protecting nutritive perfusion in a dose-dependent manner.
    Harder Y; Amon M; Schramm R; Contaldo C; Metzkow E; Matzen A; Rücker M; Vollmar B; Menger MD
    Surgery; 2009 Apr; 145(4):372-83. PubMed ID: 19303985
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Erythropoiesis stimulation in acute ischemic syndromes.
    Ruifrok WP; Lipsic E; de Boer RA; van Gilst WH; van Veldhuisen DJ
    Heart Fail Clin; 2010 Jul; 6(3):313-21. PubMed ID: 20630406
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Erythropoietin: biochemical characteristics, biologic effects, indications and results of use in hematology].
    Marmont AM
    Tumori; 1997; 83(4 Suppl 2):S3-15. PubMed ID: 9487378
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Erythropoietin alleviates post-ischemic injury of rat hearts by attenuating nitrosative stress.
    Lu MJ; Chen YS; Huang HS; Ma MC
    Life Sci; 2012 May; 90(19-20):776-84. PubMed ID: 22521289
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The use of recombinant human erythropoietin (EPO) to correct the anemia of end-stage renal disease: a progress report.
    Adamson W; Egrie JC; Browne JK; Downing MR; Eschbach W
    Behring Inst Mitt; 1988 Aug; (83):188-92. PubMed ID: 3071336
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Erythropoietin-beta in the treatment of anemia in patients with chronic renal insufficiency].
    Dimković N
    Med Pregl; 2001; 54(5-6):235-40. PubMed ID: 11759218
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Vascular endothelial growth factor is crucial for erythropoietin-induced improvement of cardiac function in heart failure.
    Westenbrink BD; Ruifrok WP; Voors AA; Tilton RG; van Veldhuisen DJ; Schoemaker RG; van Gilst WH; de Boer RA
    Cardiovasc Res; 2010 Jul; 87(1):30-9. PubMed ID: 20139114
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Survival and proliferative roles of erythropoietin beyond the erythroid lineage.
    Noguchi CT; Wang L; Rogers HM; Teng R; Jia Y
    Expert Rev Mol Med; 2008 Dec; 10():e36. PubMed ID: 19040789
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Erythropoietin biology in cancer.
    Hardee ME; Arcasoy MO; Blackwell KL; Kirkpatrick JP; Dewhirst MW
    Clin Cancer Res; 2006 Jan; 12(2):332-9. PubMed ID: 16428469
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Beneficial and ominous aspects of the pleiotropic action of erythropoietin.
    Jelkmann W; Wagner K
    Ann Hematol; 2004 Nov; 83(11):673-86. PubMed ID: 15322761
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Erythropoietin--physiology and therapeutic potentialities].
    Möllmann M
    Anasthesiol Intensivmed Notfallmed Schmerzther; 1992 Dec; 27(8):461-8. PubMed ID: 1489869
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.